First person vaccinated during trial of new Ebola ja
Oxford University researchers have administered the first dose of a new Ebola vaccine targeting the Bundibugyo strain to a human volunteer. The trial aims to assess the safety and efficacy of the vaccine, which uses technology similar to the AstraZeneca Covid-19 vaccine.
Why it matters
Developing a vaccine for the rare but deadly Bundibugyo strain of Ebola is a significant step in global pandemic preparedness and public health.
Health: First person vaccinated during trial of new Ebola ja
First person vaccinated during trial of new Ebola jab
Researchers and health organisations have since been racing to get a vaccine or treatment for the relatively rare strain to the clinical trial stage where it is tested on humans.
A volunteer was injected on Friday with the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola, driving a deadly outbreak in the Democratic Republic of Congo, Oxford University said.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in